Description of the active substance:
This information is a reference and it is not enough that the drug was prescribed by a doctor. .
NSAID, anthraquinoline derivative, diacetylated rhein derivative. Metabolizing to the active metabolite - rhein, inhibits the activity of interleukin-1, which plays an important role in the development of inflammation and cartilage degradation in osteoarthritis.
Inhibits the effect of other cytokines (including interleukin-6, TNF?). The action develops in 2-4 weeks.
Diacerein has analgesic and anti-inflammatory activity when taken orally.
After oral administration, it is rapidly absorbed from the digestive tract. At a single admission in a dose of 50 mg C max in plasma - 3.15 mg / l. T max - 144 min.Bioavailability increases by 25% with simultaneous intake with food. With repeated administration in connection with the cumulation of the drug, C max in the plasma increases. Diacerein is completely deacetylated to rhein. The binding of rhein to plasma proteins (albumin) is almost 100%. Rein penetrates the GEB and the placental barrier. T 1/2 - 255 min. It is excreted by the kidneys unchanged (20%), in the form of glucuronide (60%), in the form of sulfate - 20%.
Primary and secondary osteoarthritis.
Is taken internally. The initial dose - 50 mg 1 time / day, after 2 weeks. the dose can be increased to 50 mg 2 times / day. Treatment is conducted continuously for a long time or in courses (at least 4 months).
On the part of the digestive system: diarrhea, nausea, vomiting, abdominal pain, hepatitis.
Allergic reactions: urticaria, fever, bronchospasm, angioedema, anaphylactic shock.
Other: malaise, intense staining of urine (depending on pH) from yellow to brown (has no clinical significance).
Children and adolescence under 18; increased sensitivity to diacerein; increased sensitivity to anthraquinone laxatives.
PREGNANCY AND LACTATION
Contraindicated in pregnancy and lactation (breastfeeding).
Use with caution in severe hepatic or renal failure, intestinal obstruction, inflammatory bowel disease.
During the period of treatment, periodic monitoring of blood counts, functional liver tests (determination of the level of hepatic transaminases), urine (determination of the level of creatinine and QC) is necessary.
If the kidney function worsens, you need to lower the dose. In patients with chronic renal failure, with a QC less than 30 ml / min, the dose of diacerein should be reduced to 50 mg / day and then titrated according to tolerability and clinical efficacy.
Diacerein is not recommended for use with drugs that increase the amount of intestinal contents (for example, high amounts of fiber).
Antacids reduce the absorption of diacerein.
With simultaneous administration with antibiotics or chemotherapeutic drugs that affect the intestinal microflora, the incidence of adverse reactions from the intestine may increase.
Drugs containing aluminum hydroxide and / or magnesium hydroxide, reduce the bioavailability of diacerein.
Simultaneous use with laxatives is not recommended.